Clinical Features and Serological Markers Risk Model Predicts Overall Survival in Patients Undergoing Breast Cancer and Bone Metastasis Surgeries

BackgroundSurgical therapy of breast cancer and bone metastasis can effectively improve the prognosis of breast cancer. However, after the first operation, the relationship between preoperative indicators and outcomes in patients who underwent metastatic bone surgery remained to be studied. Purpose...

Full description

Bibliographic Details
Main Authors: Haochen Mou, Zhan Wang, Wenkan Zhang, Guoqi Li, Hao Zhou, Eloy Yinwang, Fangqian Wang, Hangxiang Sun, Yucheng Xue, Zenan Wang, Tao Chen, Xupeng Chai, Hao Qu, Peng Lin, Wangsiyuan Teng, Binghao Li, Zhaoming Ye
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.693689/full
id doaj-4b195037f1914717922140c667f4f0d6
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Haochen Mou
Haochen Mou
Haochen Mou
Zhan Wang
Zhan Wang
Zhan Wang
Wenkan Zhang
Wenkan Zhang
Wenkan Zhang
Guoqi Li
Guoqi Li
Guoqi Li
Hao Zhou
Hao Zhou
Hao Zhou
Eloy Yinwang
Eloy Yinwang
Eloy Yinwang
Fangqian Wang
Fangqian Wang
Fangqian Wang
Hangxiang Sun
Hangxiang Sun
Hangxiang Sun
Yucheng Xue
Yucheng Xue
Yucheng Xue
Zenan Wang
Zenan Wang
Zenan Wang
Tao Chen
Tao Chen
Tao Chen
Xupeng Chai
Xupeng Chai
Xupeng Chai
Hao Qu
Hao Qu
Hao Qu
Peng Lin
Peng Lin
Peng Lin
Wangsiyuan Teng
Wangsiyuan Teng
Wangsiyuan Teng
Binghao Li
Binghao Li
Binghao Li
Zhaoming Ye
Zhaoming Ye
Zhaoming Ye
spellingShingle Haochen Mou
Haochen Mou
Haochen Mou
Zhan Wang
Zhan Wang
Zhan Wang
Wenkan Zhang
Wenkan Zhang
Wenkan Zhang
Guoqi Li
Guoqi Li
Guoqi Li
Hao Zhou
Hao Zhou
Hao Zhou
Eloy Yinwang
Eloy Yinwang
Eloy Yinwang
Fangqian Wang
Fangqian Wang
Fangqian Wang
Hangxiang Sun
Hangxiang Sun
Hangxiang Sun
Yucheng Xue
Yucheng Xue
Yucheng Xue
Zenan Wang
Zenan Wang
Zenan Wang
Tao Chen
Tao Chen
Tao Chen
Xupeng Chai
Xupeng Chai
Xupeng Chai
Hao Qu
Hao Qu
Hao Qu
Peng Lin
Peng Lin
Peng Lin
Wangsiyuan Teng
Wangsiyuan Teng
Wangsiyuan Teng
Binghao Li
Binghao Li
Binghao Li
Zhaoming Ye
Zhaoming Ye
Zhaoming Ye
Clinical Features and Serological Markers Risk Model Predicts Overall Survival in Patients Undergoing Breast Cancer and Bone Metastasis Surgeries
Frontiers in Oncology
breast cancer
bone metastasis
prognosis
surgeries
Cox regression
nomogram
author_facet Haochen Mou
Haochen Mou
Haochen Mou
Zhan Wang
Zhan Wang
Zhan Wang
Wenkan Zhang
Wenkan Zhang
Wenkan Zhang
Guoqi Li
Guoqi Li
Guoqi Li
Hao Zhou
Hao Zhou
Hao Zhou
Eloy Yinwang
Eloy Yinwang
Eloy Yinwang
Fangqian Wang
Fangqian Wang
Fangqian Wang
Hangxiang Sun
Hangxiang Sun
Hangxiang Sun
Yucheng Xue
Yucheng Xue
Yucheng Xue
Zenan Wang
Zenan Wang
Zenan Wang
Tao Chen
Tao Chen
Tao Chen
Xupeng Chai
Xupeng Chai
Xupeng Chai
Hao Qu
Hao Qu
Hao Qu
Peng Lin
Peng Lin
Peng Lin
Wangsiyuan Teng
Wangsiyuan Teng
Wangsiyuan Teng
Binghao Li
Binghao Li
Binghao Li
Zhaoming Ye
Zhaoming Ye
Zhaoming Ye
author_sort Haochen Mou
title Clinical Features and Serological Markers Risk Model Predicts Overall Survival in Patients Undergoing Breast Cancer and Bone Metastasis Surgeries
title_short Clinical Features and Serological Markers Risk Model Predicts Overall Survival in Patients Undergoing Breast Cancer and Bone Metastasis Surgeries
title_full Clinical Features and Serological Markers Risk Model Predicts Overall Survival in Patients Undergoing Breast Cancer and Bone Metastasis Surgeries
title_fullStr Clinical Features and Serological Markers Risk Model Predicts Overall Survival in Patients Undergoing Breast Cancer and Bone Metastasis Surgeries
title_full_unstemmed Clinical Features and Serological Markers Risk Model Predicts Overall Survival in Patients Undergoing Breast Cancer and Bone Metastasis Surgeries
title_sort clinical features and serological markers risk model predicts overall survival in patients undergoing breast cancer and bone metastasis surgeries
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2021-09-01
description BackgroundSurgical therapy of breast cancer and bone metastasis can effectively improve the prognosis of breast cancer. However, after the first operation, the relationship between preoperative indicators and outcomes in patients who underwent metastatic bone surgery remained to be studied. Purpose 1. Recognize clinical and laboratory prognosis factors available to clinical doctors before the operation for bone metastatic breast cancer patients. 2. Develop a risk prediction model for 3-year postoperative survival in patients with breast cancer bone metastasis.MethodsFrom 2014 to 2020, patients who suffered from breast cancer bone metastasis and received therapeutic procedures in our institution were included for analyses (n=145). For patients who underwent both breast cancer radical surgery and bone metastasis surgery, comprehensive datasets of the parameters of interest (clinical features, laboratory factors, and patient prognoses) were collected (n=69). We performed Multivariate Cox regression to identify factors that were associated with postoperative outcome. 3-year survival prediction model and nomograms were established by 100 bootstrapping. Its benefit was evaluated by calibration plot, C-index, and decision curve analysis. The Surveillance, Epidemiology, and End Results database was also used for external validation.ResultsRadiotherapy for primary cancer, pathological type of metastatic breast cancer, lymph node metastasis, elevated serum alkaline phosphatase, lactate dehydrogenase were associated with postoperative prognosis. Pathological types of metastatic breast cancer, multiple bone metastasis, organ metastases, and elevated serum lactate dehydrogenase were associated with 3-year survival. Then those significant variables and serum alkaline phosphatase counts were integrated to construct nomograms for 3-year survival. The C-statistic of the established predictive model was 0.83. The calibration plot presents a graphical representation of calibration. In the decision curve analysis, the benefits are higher than those of the extreme curve. The receiver operating characteristic of the external validation of the model was 0.82, indicating a favored fitting degree of the two models.ConclusionOur study suggests that several clinical features and serological markers can predict the overall survival among the patients who are about to receive bone metastasis surgery after breast cancer surgery. The model can guide the preoperative evaluation and clinical decision-making for patients. Level of evidence Level III, prognostic study.
topic breast cancer
bone metastasis
prognosis
surgeries
Cox regression
nomogram
url https://www.frontiersin.org/articles/10.3389/fonc.2021.693689/full
work_keys_str_mv AT haochenmou clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT haochenmou clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT haochenmou clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT zhanwang clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT zhanwang clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT zhanwang clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT wenkanzhang clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT wenkanzhang clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT wenkanzhang clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT guoqili clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT guoqili clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT guoqili clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT haozhou clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT haozhou clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT haozhou clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT eloyyinwang clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT eloyyinwang clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT eloyyinwang clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT fangqianwang clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT fangqianwang clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT fangqianwang clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT hangxiangsun clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT hangxiangsun clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT hangxiangsun clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT yuchengxue clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT yuchengxue clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT yuchengxue clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT zenanwang clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT zenanwang clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT zenanwang clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT taochen clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT taochen clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT taochen clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT xupengchai clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT xupengchai clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT xupengchai clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT haoqu clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT haoqu clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT haoqu clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT penglin clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT penglin clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT penglin clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT wangsiyuanteng clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT wangsiyuanteng clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT wangsiyuanteng clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT binghaoli clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT binghaoli clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT binghaoli clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT zhaomingye clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT zhaomingye clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
AT zhaomingye clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries
_version_ 1717377560409538560
spelling doaj-4b195037f1914717922140c667f4f0d62021-09-17T05:27:45ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-09-011110.3389/fonc.2021.693689693689Clinical Features and Serological Markers Risk Model Predicts Overall Survival in Patients Undergoing Breast Cancer and Bone Metastasis SurgeriesHaochen Mou0Haochen Mou1Haochen Mou2Zhan Wang3Zhan Wang4Zhan Wang5Wenkan Zhang6Wenkan Zhang7Wenkan Zhang8Guoqi Li9Guoqi Li10Guoqi Li11Hao Zhou12Hao Zhou13Hao Zhou14Eloy Yinwang15Eloy Yinwang16Eloy Yinwang17Fangqian Wang18Fangqian Wang19Fangqian Wang20Hangxiang Sun21Hangxiang Sun22Hangxiang Sun23Yucheng Xue24Yucheng Xue25Yucheng Xue26Zenan Wang27Zenan Wang28Zenan Wang29Tao Chen30Tao Chen31Tao Chen32Xupeng Chai33Xupeng Chai34Xupeng Chai35Hao Qu36Hao Qu37Hao Qu38Peng Lin39Peng Lin40Peng Lin41Wangsiyuan Teng42Wangsiyuan Teng43Wangsiyuan Teng44Binghao Li45Binghao Li46Binghao Li47Zhaoming Ye48Zhaoming Ye49Zhaoming Ye50Department of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaBackgroundSurgical therapy of breast cancer and bone metastasis can effectively improve the prognosis of breast cancer. However, after the first operation, the relationship between preoperative indicators and outcomes in patients who underwent metastatic bone surgery remained to be studied. Purpose 1. Recognize clinical and laboratory prognosis factors available to clinical doctors before the operation for bone metastatic breast cancer patients. 2. Develop a risk prediction model for 3-year postoperative survival in patients with breast cancer bone metastasis.MethodsFrom 2014 to 2020, patients who suffered from breast cancer bone metastasis and received therapeutic procedures in our institution were included for analyses (n=145). For patients who underwent both breast cancer radical surgery and bone metastasis surgery, comprehensive datasets of the parameters of interest (clinical features, laboratory factors, and patient prognoses) were collected (n=69). We performed Multivariate Cox regression to identify factors that were associated with postoperative outcome. 3-year survival prediction model and nomograms were established by 100 bootstrapping. Its benefit was evaluated by calibration plot, C-index, and decision curve analysis. The Surveillance, Epidemiology, and End Results database was also used for external validation.ResultsRadiotherapy for primary cancer, pathological type of metastatic breast cancer, lymph node metastasis, elevated serum alkaline phosphatase, lactate dehydrogenase were associated with postoperative prognosis. Pathological types of metastatic breast cancer, multiple bone metastasis, organ metastases, and elevated serum lactate dehydrogenase were associated with 3-year survival. Then those significant variables and serum alkaline phosphatase counts were integrated to construct nomograms for 3-year survival. The C-statistic of the established predictive model was 0.83. The calibration plot presents a graphical representation of calibration. In the decision curve analysis, the benefits are higher than those of the extreme curve. The receiver operating characteristic of the external validation of the model was 0.82, indicating a favored fitting degree of the two models.ConclusionOur study suggests that several clinical features and serological markers can predict the overall survival among the patients who are about to receive bone metastasis surgery after breast cancer surgery. The model can guide the preoperative evaluation and clinical decision-making for patients. Level of evidence Level III, prognostic study.https://www.frontiersin.org/articles/10.3389/fonc.2021.693689/fullbreast cancerbone metastasisprognosissurgeriesCox regressionnomogram